Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis.
about
Bronchoscopy-guided antimicrobial therapy for cystic fibrosisInhaled mannitol for cystic fibrosisVitamin K supplementation for cystic fibrosisInterventions for improving adherence to treatment in cystic fibrosisTopical nasal steroids for treating nasal polyposis in people with cystic fibrosisStandard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisVitamin E supplementation in people with cystic fibrosisAntibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosisImmunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosisRecombinant growth hormone therapy for cystic fibrosis in children and young adultsInterventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosisEradication therapy for Burkholderia cepacia complex in people with cystic fibrosisPsychological interventions for individuals with cystic fibrosis and their familiesPneumococcal vaccines for cystic fibrosisAntibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosisVitamin K supplementation for cystic fibrosisAntibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosisNebuliser systems for drug delivery in cystic fibrosisTopical nasal steroids for treating nasal polyposis in people with cystic fibrosisAntibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbationEradication therapy for Burkholderia cepacia complex in people with cystic fibrosisPneumococcal vaccines for cystic fibrosisInterventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisImmunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosisRecombinant growth hormone therapy for cystic fibrosis in children and young adultsInhaled antibiotics for pulmonary exacerbations in cystic fibrosisAntibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosisAntibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisStandard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisInterventions for the eradication of methicillin resistant Staphylococcus aureus in people with cystic fibrosisAutogenic drainage for airway clearance in cystic fibrosisTopical nasal steroids for treating nasal polyposis in people with cystic fibrosisAntibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbationVitamin K supplementation for cystic fibrosisStandard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisImmunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosisVitamin E supplementation in people with cystic fibrosis
P2860
Q24186413-331410D0-7869-4803-9B2A-ADF1A62854B6Q24186558-6F4646D1-1930-413F-9194-02AA53D63592Q24186592-C3413229-54B3-428A-8A7A-E4011483A16CQ24186754-FBBDB6CA-A16D-42AB-9E15-91BD4C9CFCE8Q24187053-8A8A37FD-8BA6-4CEE-B4F6-2F4B5DFA3965Q24187383-320F124F-F77A-47A6-AB0D-D85D798357A5Q24187397-DD9F72F7-030D-476E-B1FE-E48380E5FD66Q24187458-664F8519-70CD-426D-8BBF-0CE149ACEEEFQ24187829-DC5AF7ED-90E8-43D1-AB9B-5446748AC63CQ24187892-99889E05-6956-4C28-9155-A7489E139C3CQ24187987-E24A420B-3ECD-4471-9DB2-9E019CEB4B2AQ24193082-B471A269-30C6-4A06-9CE3-563FA33EB979Q24193892-BA9173E6-CB7A-4E9D-A3B8-4D81617A0B08Q24194469-EE1BF786-47F2-4B63-9108-0A462052D1FDQ24197517-E06707E1-CF08-4759-9607-A79BB14E52DDQ24197634-01824BC4-E661-4A08-8798-9E472939E4E0Q24197766-55221F4B-132C-4271-95CA-EC1D9F4A8934Q24197879-E3A250AA-20AC-49F6-ABF6-E988FCB84B38Q24197927-3018F25B-786C-477F-8B69-B400D6F6F1BFQ24198135-6E953ED9-0846-47E0-93F3-A066DCBE6F6CQ24198175-09A1AC93-EE66-41F8-AE0C-E7D6DB06503BQ24200312-6A2EFEEE-80AB-4AD2-8BCC-DDC2AB5B260FQ24200822-A149D087-0FCF-4064-A36D-50C84E5E00C9Q24201620-55585A80-F24E-48E3-A6B5-2A1A36FE1105Q24201868-CB192A52-18F4-4606-A711-A59964A9113FQ24202203-419631C8-C644-4F64-BA65-350E9FF3C8D5Q24202283-F0EC9BA2-C628-4D24-85F4-C73AD89A1EE9Q24202353-CD0A1DCD-04A3-416A-84CC-05A37C89925EQ24202502-190CAAE4-7A58-4341-8FBF-C500D47EEB7FQ24202879-269A6637-592B-4CDE-86E4-315D94C9800FQ24203005-135B6FB6-0DC4-4AB5-9FB0-A76DECD525DAQ24203763-7C54C45D-4B96-45DF-B6C8-F3D5B98BFD17Q24203947-AB819008-D0BD-4D83-A321-B53E842A330BQ24234445-05666E73-31E9-47EF-8524-210DA1A4FCE0Q24234854-81304D72-EA5C-418C-8E44-08DE711E359FQ24234866-367A8700-784F-4243-BC44-7D4A36E82632Q24234955-68B4EBC3-3DD4-4090-A75B-0721E0E84D78Q24234964-2DBC709E-0D75-4A7B-8903-3B647073D079Q24235470-3FAAE442-4234-4737-B9D7-256344ED0B15Q24235745-6A43FC71-5282-469B-9281-7C2775234B60
P2860
Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Development of a disease speci ...... lescents with cystic fibrosis.
@ast
Development of a disease speci ...... lescents with cystic fibrosis.
@en
Development of a disease speci ...... lescents with cystic fibrosis.
@nl
type
label
Development of a disease speci ...... lescents with cystic fibrosis.
@ast
Development of a disease speci ...... lescents with cystic fibrosis.
@en
Development of a disease speci ...... lescents with cystic fibrosis.
@nl
prefLabel
Development of a disease speci ...... lescents with cystic fibrosis.
@ast
Development of a disease speci ...... lescents with cystic fibrosis.
@en
Development of a disease speci ...... lescents with cystic fibrosis.
@nl
P2093
P2860
P921
P356
P1433
P1476
Development of a disease speci ...... lescents with cystic fibrosis.
@en
P2093
P2860
P304
P356
10.1136/THORAX.55.11.946
P407
P577
2000-11-01T00:00:00Z